Showing results (71-80 of 88) with videos related to
Sort By:
Pageof 9
Neurology|April 8, 2016
A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystoniaElodie Hainque, Marie Vidailhet, Nathalie Cozic, et al.Plos One|January 7, 2021
Personality dimensions of patients can change during the course of parkinson's diseaseMathilde Boussac, Christophe Arbus, Julia Dupouy, et al.Journal of Parkinson'S Disease|July 24, 2022
Can Dopamine Responsiveness Be Predicted in Parkinson's Disease Without an Acute Administration Test?Nacim Betrouni, Caroline Moreau, Anne-Sophie Rolland, et al.The Lancet. Neurology|April 16, 2022
Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover studyValérie Cochen De Cock, Pauline Dodet, Smaranda Leu-Semenescu, et al.Journal of Parkinson'S Disease|June 27, 2025
Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's diseaseMathilde Boussac, Florent Faggianelli, Estelle Harroch, et al.Journal of Parkinson'S Disease|December 13, 2021
Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson's Disease (PSYCHO-STIM II)Mathilde Boussac, Christophe Arbus, Helene Klinger, et al.Journal of Parkinson'S Disease|February 20, 2025
Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studiesDavid Devos, Olivier Rascol, Wassilios G Meissner, et al.Clinical Parkinsonism & Related Disorders|February 20, 2026
Effects of deep brain stimulation on non motor fluctuations in Parkinson's disease (assessed with the NMF severity scale)Christian Matta, Camille Comet, Corentin Gaillard, et al.NPJ Parkinson'S Disease|August 2, 2025
Classification of GBA1 variants and their impact on Parkinson's disease: an in silico score analysisAymeric Lanore, Christelle Tesson, Aymeric Basset, et al.BMJ Neurology Open|January 21, 2026
Understanding dopaminergic dose reduction following STN-DBS: mediation analysisAymeric Lanore, Marion Houot, Aymeric Basset, et al.Pageof 9